MAPK8 and renal cell carcinoma: In the primary human RCC cells (“RCC1”), SC66 treatment similarly reduced ROS production (Fig. 4k), mitochondrial depolarization (Fig. 4l), ceramide accumulation(Fig. 4m) and JNK activation (Fig. 4n).